Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Escalating-Doses of Bendamustine for Patients With Previously Treated Multiple Myeloma

NCT02315157 is registered in ClinicalTrials.gov with Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University as lead sponsor.

NCT NCT02315157
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02315157 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Escalating-Doses of Bendamustine for Patients With Previously Treated Multiple Myeloma
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase
Phase 1
Overall status
Withdrawn
Start date
June 30, 2014
Completion date
November 30, 2018
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, plasma cell leukemia